Bookmark
Forward
QuickView for Dapiprazole (compound)
PubChem
| Name: | dapiprazole |
|---|---|
| PubChem Compound ID: | 3033538 |
| Molecular formula: | C19H27N5 |
| Molecular weight: | 325.451 g/mol |
| Synonyms: |
Dapirazolum [INN-Latin]; Reversil; DAPIRAZOLE; Dapirazol [INN-Spanish]; Dapiprazol [German]; 1,2,4-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine; Glamidolo; 72822-12-9; DAPIPRAZOLE
|
DrugBank
Identification
| Name: | dapiprazole |
|---|---|
| Name (isomeric): | DB00298 |
| Drug Type: | small molecule |
| Brand: | Rev-Eyes |
| Category: | Ophthalmologicals, Antimydriatics, Adrenergic alpha-Antagonists, Antipsychotic Agents |
| CAS number: | 72822-12-9 |
Pharmacology
| Indication: | Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations. |
|---|---|
| Pharmacology: |
Dapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP eithe...
show more » |
| Mechanism of Action: | Dapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens. |
| Absorption: | Systemic absorption is negligible. |
| Toxicity: | Oral LD50 is 1189-2100 mg/kg in mice, rats and rabbits. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
